Since the creation of this platform, an editorial board made up of experts in the management of HIV patients from all over Europe was formed to review and ensure the quality of the content.
Juan Ambrosioni MD, Ph.D., is an infectious diseases specialist at the University of Buenos Aires, Argentina, and of the University of Geneva, Switzerland. He works as an infectious diseases specialist at the Infectious Diseases Service of Hospital Clinic, Barcelona and as Junior Team Leader of IDIBAPS. He has published more than 90 articles indexed in PubMed (more than 30 as the first author) in the field of infectious diseases, in particular, HIV / AIDS infection. He is Associate Professor of Infectious Diseases and AIDS at the University of Barcelona, Spain, and he is a reviewer of the main journals of the field. His main research interests are primary HIV infection, opportunistic infections and pharmacology (including resistance) of antiretroviral drugs and antimicrobials.
David Back is Emeritus Professor of Pharmacology at the University of Liverpool and has led studies on Clinical Pharmacology and drug interactions of antiretrovirals and HCV drugs. David has authored ~500 publications, is a former Editor of British Journal of Clinical Pharmacology and is the scientific lead on the online resources eg www.hiv-druginteractions.org & www.hep-druginteractions.org. In 2007 he was awarded the BPS Lilly Prize for outstanding contribution to Clinical Pharmacology and in 2015 an EACS Lifetime achievement award.
Dr. Marta Boffito, MD, Ph.D., FRCP, is a Consultant physician at Chelsea and Westminster Hospital, and Reader at Imperial College, London, London UK. She is the Clinical Research Lead of the Clinical Research Facility and HIV Service Lead at Chelsea and Westminster Hospital, where she runs numerous research projects and clinical trials, she consults on complex pharmacological issues, sees patients with HIV (she founded the first HIV over-50-years clinic in London, UK), and teaches HIV medicine and pharmacology at Imperial College London and in various National and International settings. She trained in Italy, the USA, and the UK and has a special interest in antiretroviral drug pharmacology: from prevention to treatment. In these areas, she contributes to the educational, scientific, and guideline-formulation activities of national bodies including the British HIV Association. She has published over 150 peer-reviewed articles, editorials, and reviews. She has been involved in capacity building programmes for resource-limited settings (e.g. Uganda) and is an applicant on numerous successful collaborative grants.
David Burger (Oct. 20, 1964) received his Pharmacy Degree at the Utrecht University in 1990 and completed his Ph.D. thesis in 1994. After this, he moved to the Radboud University Medical Centre, Nijmegen, for his hospital pharmacist training. Since 1997 he has been leading a research group focussing on the clinical pharmacology of antimicrobial agents with emphasis on HIV, TB, fungal infections, and Hepatitis. He is a member of the Editorial Board of the www.hiv-druginteractions.org and www.hep-druginteractions.org websites. He is an Executive Editor of BJCP and serves on the editorial boards of TDM, JAIDS, JAC, Antiviral Therapy. Since April 2011 he has been appointed as a Professor of Clinical Pharmacy at the Radboud University Nijmegen. He is (co-) author of more than 450 publications in this field and has supervised 27 completed Ph.D. theses. The topics of his interest are drug-drug interactions, pediatric pharmacology, therapeutic drug monitoring, and operational research in resource-limited countries.
He is temporary Assistant Professor at the University of Torino (Department of Medical Sciences, Infectious Diseases); he has obtained the National Qualification for Associate (2017) and Full (2018) Professor in Infectious Diseases. He is Consultant in Infectious Diseases at the University of Torino, Torino, Italy). He obtained the Diploma in Tropical Medicine and Hygiene (Mahidol University, Bangkok, Thailand). He is member of the Panel of the Italian Guidelines on the Use of Antiretrovirals and Management of patients living with HIV and of the Scientific Committee of the Italian Cohort of HIV-positive patients (ICONA), of the Italian Cohort of HIV-positive Geriatric Patients (GEPPO) and of the Italian Registry of Non-tubercular Mycobacteria (IRENE). He is Associate Editor of “BMC Infectious Diseases, “Infectious Diseases and Tropical Medicine” and “PlosOne” Journals. Since 2016 he is member of the Governing Council of the Italian Society of Infectious Diseases (SIMIT). He has experience as a Consulting Physician in Infectious Diseases and Tropical Medicine (Sudan, Thailand, Burundi); several phase II, III and IV studies in antiretroviral treatment trials. In 2014 he helped setting a collaboration with the Infectious Disease Institute, Makerere University, Kampala, Uganda with the aim of improving key features of HIV Research (pharmacogenetics and co-morbidities). His main field of interest is the clinical pharmacology and pharmacogenetics of anti-infective agents (antiretrovirals, antibiotics, antifungals) and the central nervous system complication of HIV-infection.
Dr. Cortes is a specialist in infectious diseases and internal medicine. Since 2005, have been dedicated to HIV/AIDS in both patient care and research. She has a position as Associate Professor at the University of Chile with academic activities involving undergraduate, postgraduate, and doctoral students. Dr. Cortes has worked at Fundación Arriarán, Chile's first and largest HIV treatment center, for more than 16 years, where she has clinical duties in the care of PLWH. She has served on the Chilean Infectious Diseases Society's HIV advisory group as a member and chair (SOCHINF). She is the former vice president of SOCHINF. She works as an acting consultant for the Chilean Ministry of Health, where she has contributed to the establishment and revision of national clinical guidelines for HIV/AIDS care, as well as participation in several committees focused on HIV prevention, testing, and treatment initiatives. She is currently a member of the Ministry of Health's COVID-19 national guidelines advisory council.
Adrian Curran graduated in Medicine at the Universitat Autònoma de Barcelona, Spain. He obtained his specialty in Internal Medicine in 2005 at the Hospital Universitari Vall d’Hebron, Barcelona, where he works in the HIV Unit. In 2012 he obtained his Ph.D. Cum Laude with a thesis about body composition alterations secondary to ART. His main areas of interests within HIV-infection are long-term side effects of ART, the pharmacokinetics of ART and drug-drug interactions, sexually transmitted diseases including HPV infection and HIV-Tuberculosis co-infection. He is the author of book chapters on antiretroviral treatment side effects, has published in national and international journals, has collaborated in peer reviewing of international medical journals and has participated in international clinical trials.
Gordana Dragovic Lukic is a MD, Ph.D., specialist in clinical pharmacology. She obtained her MD in 1997 and completed her specialisation in clinical pharmacology in 2003, both at the School of Medicine, University of Belgrade. In 2000 she has joined the HIV/AIDS Center of the Infective diseases clinic, University teaching hospital in Belgrade, Serbia. Dr. Gordana obtained her Ph.D. degree in 2008 at the School of Medicine, University of Belgrade. Since 2015, she is appointed as Associate Professor of Pharmacology and Clinical Pharmacology at the University of Belgrade, Serbia. Currently, she is a Head of the Pharmacokinetic Unit of the antiretroviral drugs at the School of Medicine, University of Belgrade. The research activity of Gordana Dragovic Lukic has focused mainly on the clinical pharmacology of antiretroviral drugs, population pharmacokinetics, pharmacogenomics of antiretrovirals and drug-drug interactions.
Robert Güerri-Fernández is an Internal Medicine - Infectious Diseases - HIV care provider with a deep concern for the long-term consequences of chronic infections. Comorbidities and polypharmacy are one of the most important issues in real life HIV patients. Dr. Güerri-Fernández research interests' are in understanding and modeling the mechanism of chronic comorbidities in HIV infected individuals. With a background in his Ph.D. training on investigating the role of chronic immune activation in HIV comorbidities, especially bone toxicity. He has studied bone deterioration due to the continuous activation of the immunoskeletal interphase. While a research fellow he has studied the prevalence of bone impairment among the HIV population with two population-based studies that have been cited extensively. As a junior faculty, he has designed and lead several clinical trials and he has been leading, as Principal Investigator, two major projects funded by the Spanish Ministry of Health-ISCIII (PI13/00589 and PI16/01860) that are unveiling the importance of the chronic inflammation in bone impairment on HIV. Recently, he has been working in a postdoctoral position with Prof David Asmuth at the University of California, Davis to learn about how the immune reconstitution and the immune profile impacts on HIV related comorbidities.
Dr. Imaz was graduated in Medicine from the Medical School of the University of Navarra (Pamplona, Spain) in 2002. He completed his fellowship in Internal Medicine at Vall d’Hebron University Hospital (Barcelona, Spain) in 2008 and obtained his Ph.D. degree in 2012 in the Autonomous University of Barcelona. Since 2010 he works in the Infectious Diseases Department of the Bellvitge University Hospital, a large referral hospital covering the southern metropolitan area of Barcelona and specifically in the HIV and STI Unit. He is also involved in clinical trials and investigations in the field of HIV infection and antiretroviral therapy. His main areas of interest are: antiretroviral resistance and salvage therapy, antiretroviral combinations, and antiretroviral drugs penetration and activity in reservoirs/tissue compartments.
Professor Saye Khoo, MD, Ph.D., is an Honorary Consultant Physician in Infectious Diseases at the Royal Liverpool University Hospital, and Professor in the Institute of Translational Medicine at the University of Liverpool. His research focuses on the pharmacology of HIV treatment failure and how therapy may be improved through individualized care through understanding of why drug exposure varies markedly between individuals (and the role of individual characteristics such as weight, gender, host genetics, and drug interactions), and identify vulnerable groups who are at particular risk of failure, or toxicity. These studies span bench science, through translational research and into the clinic, and onwards to population-based modeling approaches.
Sonia Luque obtained a Degree in Pharmacy at the University of Barcelona in 2000. She completed her Ph.D. in Medicine at the University Autònoma de Barcelona in 2009. She is a faculty member as a Clinical Pharmacist at the Pharmacy Department Hospital del Mar Barcelona since 2004. She has a Master's Degree in Application and Control of Antimicrobial Therapy of Universitat Autónoma of Barcelona. She has been working in the study of the pharmacokinetics and pharmacodynamics (PK/PD) of antimicrobials and she is currently involved in various national and international research projects. In the last years, she has been working in the field of HIV treatment, especially in the area of antiretroviral drug interactions. Sonia is a member of the panel of AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and of the Pharmacokinetics/Pharmacodynamics (PK/PD) of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). She has published over 30 articles in the field of the Infectious Diseases. The topics of her interest are drug-drug interactions, HIV and pharmacokinetics, and pharmacodynamics
Catia Marzolini obtained a degree in Pharmacy followed by a Ph.D. in Clinical Pharmacology at the University of Lausanne, Switzerland. She completed a post-doctoral fellowship in the field of pharmacogenetics of drug transporters within the Division of Clinical Pharmacology at Vanderbilt University, Nashville, USA. Catia Marzolini is currently working as an Associate Professor in the Division of Infectious Diseases & Hospital Epidemiology at the University Hospital of Basel. Her research focuses on pharmacological determinants of antiretroviral drug response with a particular interest for the simulation of antiretroviral drug pharmacokinetics and drug-drug interactions in special populations as well as prescribing issues in elderly individuals living with HIV. Catia Marzolini is also a member of the Liverpool HIV drug-drug interactions website where she leads the content development of the website. She currently serves on the European AIDS Clinical Society (EACS) guidelines committee where she leads the drug-drug interaction section and is a member of the scientific board of the Swiss HIV Cohort Study.
Dr. José Moltó is a clinical physician in the HIV Clinic of the Hospital Universitari Germans Trias i Pujol in Badalona, Spain. He obtained his MD from the University of Alicante in 1996 and completed his internal medicine training in the Hospital General Universitario de Elche (Alicante). Since his very early medicine studies, Dr. Moltó was interested in infectious diseases, particularly in HIV infection. He joined the HIV Clinic of the Hospital Universitari Germans Trias i Pujol in 2002, and he obtained his Ph.D. degree from the Universitat Autònoma de Barcelona in 2008. He is committed with HIV research with a special interest in the clinical pharmacology of antiretroviral treatment, including population pharmacokinetics and drug-drug interactions.
Nadia Naous is the lead pharmacist for HIV and GUM at Chelsea and Westminster Hospital and the Chair of the UK HIV Pharmacy Association. She graduated from Nottingham School of Pharmacy in 2005, worked as a community pharmacist for two years before undertaking residency at Chelsea and Westminster Hospital. In 2010 she moved to Imperial College NHS Trust to become a specialist, then Lead HIV Pharmacist before returning to Chelsea and Westminster in 2019. Here she leads the HIV and GUM pharmacy service across seven clinics in inner and outer London, Hertfordshire and Essex. Nadia has been qualified and an independent non-medial prescriber since 2012. She has a special interest in the pharmacology of antiretrovirals and drug-drug interactions and has contributed to national guidance for both the British Association for Sexual Health and HIV (BASHH) and the British HIV Association (BHIVA) and works closely with the Royal Pharmaceutical Society in the development of specialist curricula, credentialing of consultant pharmacists and development of national training programmes.
Gilles Peytavin, PharmD, Ph.D., is Director of the Pharmacology-Toxicology Laboratory in the Assistance Publique des Hôpitaux de Paris-Bichat-Claude Bernard Hospital (Paris, France). He is considered in France as an expert on the clinical Pharmacology of drugs for HIV/AIDS and related infections, including viral infections and tuberculosis. His scientific contributions include work on the roles of PK/PD relationships (particularly with HIV resistance mutations), drug-drug interactions, medication adherence, and Therapeutic Drug Monitoring for management of HIV/AIDS in real life. He participates as Pharmacological Investigator in a lot of clinical trials supported by the French Agency for Research on AIDS and Viral Hepatitis (ANRS). Recently, he serves as Vice-Chair of the Pharmacological Group of the ANRS.
Dr. Jesús Troya is a clinical physician in the HIV Clinic of the Hospital Universitario Infanta Leonor in Madrid, Spain. He obtained his MD from the University Autónoma of Madrid in 2000 and completed his internal medicine training in the Hospital Virgen de la Salud (Toledo) in 2006. Since his internal medicine training, Dr. Troya was interested in HIV and viral hepatitis infections. He joined the HIV Clinic of the Hospital Universitario Infanta Leonor in 2008, and he obtained his Ph.D. degree from the Complutense University of Madrid in 2018. He is committed to HIV research with a special interest in drug-drug interactions, alternative antiretroviral strategies, and opportunistic infections.
Montse Tuset obtained a degree in Pharmacy at the University of Barcelona in 1988. She completed her Ph.D. titled “Interactions of antiretroviral drugs: from theory to clinical practice. A retrospective study of a cohort of 2140 patients seen in the Ambulatory Pharmacy Unit of the Hospital Clínic de Barcelona” at the University of Barcelona, Spain, in 2006. She has been working as a Clinical Pharmacist at the Hospital Clinic Barcelona since 1993. She is author and Editor of the Spanish Antiretroviral drug-drug interactions website www.interaccionesvih.com. She is a teacher collaborator of the Master of AIDS of the University of Barcelona since 1996. Montse has been a member of the panel of AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan guidelines committee for the consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus until 2022. She has published over 30 articles and 45 book chapters in the field of HIV, mainly drug-drug interactions. The topics of her interest are drug-drug interactions, HIV and Internal Medicine.